Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy: Urothelial carcinoma subgroup analysis

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA
Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy: Urothelial carcinoma subgroup analysis ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )
18 Feb 2019

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC

Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA
KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC ( Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA )
18 Feb 2019

CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma

Prof Nizar Tannir - MD Anderson Cancer Center, Houston, USA
CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma ( Prof Nizar Tannir - MD Anderson Cancer Center, Houston, USA )
16 Feb 2019

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA
STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )
15 Feb 2019

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer

Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK
Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer ( Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK )
15 Feb 2019

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )
14 Feb 2019

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
14 Feb 2019

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA
ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )
14 Feb 2019

Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )
14 Feb 2019

Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma

Dr Jean-Michel Lavoie - BC Cancer, Vancouver, Canada
Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma ( Dr Jean-Michel Lavoie - BC Cancer, Vancouver, Canada )
14 Feb 2019

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
14 Feb 2019

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

Dr Arjun Balar - NYU Langone Health, New York City, USA
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer ( Dr Arjun Balar - NYU Langone Health, New York City, USA )
14 Feb 2019